Issue link: http://osercommunicationsgroup.uberflip.com/i/265900
C h a i n D r u g s t o r e D a i l y Tu e s d a y, A u g u s t 1 3 , 2 0 1 3 5 0 by Actavis' commitment to meeting current and future customer needs through smart investments in R&D. Today, the new Actavis has a U.S. generics pipeline that includes nearly 185 ANDAs on file, approximately 50 of which are first-to-file applications. Given the company's impressive track record in delivering key first-to-market launches, current strong U.S. portfolio and industry-leading customer service levels, it is clear why Actavis holds a leadership position in the highly com- petitive U.S. market. Learn more about the new Actavis at NACDS booth 2121 or visit www.actavis.com. Actavis (Cont'd. from p. 4) flagship product for retail pharmacy, Safety Rx, is built on the healthcare industry's leading safety reporting plat- form– Quantros Safety and Risk Management– which currently supports more than 1,000 acute care hospitals, facilities and ambulatory provider organi- zations. Safety Rx is the one solution to meet the need for medication error and privacy incident data collection, manage- ment, analysis and reporting needs. CDD: What would you say makes your company unique? KH: At Quantros, we take healthcare safety and quality seriously and personal- ly. Many on our staff are clinical providers with domain experience in safety, quality and risk management, led by a physician Chief Medical Officer. Managing patient care to better out- comes, lower cost, and improve patient safety and satisfaction are ingrained in our mission. The personal stories of med- ical errors are our everyday motivation. CDD: What products do you see as being most important for chain drug stores this year? KH: Safety and reporting solutions are only going to increase in prominence. As healthcare, including retail pharmacy, shifts toward greater transparency, more regulated safety and quality and an emphasis on patient satisfaction, a prod- uct like Quantros Safety Rx become more essential. This product addresses all of these areas, especially when integrated Quantros (Cont'd. from p. 1) with our federally-listed Patient Safety Organization (PSO), the Quantros Patient Safety Center. CDD: What distinguishes your products from the competition? KH: Safety Rx is the first comprehensive safety and privacy management solution that is purpose-built for pharmacy chains. It is also the only solution designed to integrate seamlessly with our PSO. CDD: Who within pharmacies use your products? KH: Pharmacists and technicians are the primary reporters of data into the system, but the software ultimately benefits the chain's management and leadership at all levels, who must manage safety, quality, patient satisfaction, legal/regulatory compliance and risk for their organiza- tions. And obviously, the ultimate benefi- ciary is the patient, who receives the right medication and enjoys the privacy for sensitive healthcare information that he or she expects. CDD: What is your outlook in general for this product line? KH: Safety Rx has was launched at NACDS last year and we have already seen an impressive adoption by large national chains. We are confident this is just the start to what will become an industry standard. For more information, visit booth 3145 at the NACDS Total Store Expo or go online to www.quantros.com. Enhancing Serum. Founded in 2008, the privately held company prides itself on 'Bringing Consumers Heroic Solutions for Life's Inconveniences," with a range of innovative product offerings. CDD: What is your most successful product? RT: ROCASUBA, Inc was the first to bring an eyelash serum into the mass market in 2008. RapidLash Eyelash and Eyebrow Enhancing Serum has remained a leader in the category. Only two years after launch, RapidLash was in 24,000 stores with over one million units sold. Today, ROCASUBA contin- ues to see success with RapidLash, as it remains a go-to product for lash and brow enhancement for celebrities, con- sumers, beauty editors and make-up artists alike. CDD: What distinguishes your product from the competition? RT: What's unique about RapidLash compared to other serums on the mar- ket is its proprietary Hexatein™1 Complex, an innovative mix of six highly effective ingredients perfectly balanced to help enhance the appear- ance of more beautiful, lush-looking lashes and a fuller, bolder brows. The key for all lash enhancing products is to use these specific types of proteins and peptides that have effective proper- ties to make your lashes and brow look healthier. It is the synergistic cocktail of potent polypeptides and amino acids, vital proteins, vitamins that deliver results consumers are seeking. With nightly use on lashes and brows, users can see results in as little as 30 days. RapidLash is free of harmful ingredients including parabens, and is suitable for contact lens wearers. ROCASUBA (Cont'd. from p. 1) CDD: Who are your target end-users? RT: Both women and men alike who are looking for a solution for sparse eyebrows and eyelashes. RapidLash can help people achieve a more healthy, youthful appear- ance. And for women who may want an alternative to permanent make-up or abra- sive lash extensions, RapidLash can help attain the current beauty trends where the appearance of longer, fuller looking lashes and natural, bold brows are in! CDD: What do you anticipate to be your greatest challenge in the year ahead? RT: There have been and continue to be many product entrants into the marketplace that claim they do the same as RapidLash. Some overreach their claims and most of these products are truly just conditioners. On the other end, there have been a couple of lash serums that have been pulled from U.S. marketplace. ROCASUBA, Inc will put emphasis on consumer outreach and education. RapidLash is safe, ophthalmolo- gist and dermatologist tested, safe for con- tact lens wearers, paraben free, fragrance free and effective. CDD: What else would you like to share about your company? RT: ROCASUBA, Inc donates 5 percent of RapidLash company profits to cancer research throughout the year. With a notable list of celebrity and consumer fans, RapidLash continues to deliver stel- lar results at a price point that consumers can afford. For more information, visit booth 4056 at theNACDS Total Show Expo, go online to www.rapidlash.com, call 508-539-7077 or email roberttrow@aol.com. For more information about RapidLash, contact Nicole Pigott at 508-539-7077 or nicole@rocasuba.com. TAGI PHARMA PLANS FOR GROWTH IN GENERICS An interview with Tom Anderson, Executive President, TAGI Pharma, Inc. CDD: Tell out readers about your com- pany. What's your main line of business? TA: TAGI was launched in April 2011 as a specialty pharmaceutical company focused on the generic market, and is a wholly owned subsidiary of Precision Dose, Inc. This is Precision Dose's 10th year of operation, focusing on the hospi- tal and institutional markets with a broad portfolio of liquid products in a unit dose format. TAGI was set up as a separate entity in order to provide the focus required to successfully penetrate the retail segment with a product portfolio derived from licensing, acquisition and development activities. CDD: What would you say makes your company unique? TA: TAGI and Precision Dose as a com- bined entity places us in a unique posi- tion to take advantage of available gener- ic product opportunities across all cus- tomer segments. CDD: Tell our readers about your trade show objectives, plans, products, promo- tions, etc. TA: We will be communicating with cur- rent and potential customers of TAGI Pharma about business opportunities around products launched as well as in our pipeline. In addition, we will be reviewing our programs to drive move- ment of those products through our dis- tribution and retail partners, utilizing telemarketing activities, stocking pro- grams, and social media initiatives to cre- ate demand. CDD: Are you introducing any new products? TA: To date in 2013, we have launched Alendronate Sodium Oral Solution, the only FDA Orangebook AA-rated generic to Fosamax ® oral solution, the Phentermine 30mg and 15mg capsule products and the Codeine Sulfate Oral Solution unit dose line extension for Precision Dose's hospi- tal segment. In the remainder of this year, we expect to introduce two additional generic products and 2 unit dose line extensions that will be marketed through Precision's Dose. CDD: To what do you attribute your company's success? TA: A thorough understanding of the markets we compete and identification of profitable product opportunities, which provides a significant value-add with our product development and manufacturing partners. In addition, we ensure product quality and high service level perform- ance that drives customer loyal- ty. Finally, the ability to lever- age the Precision Dose Operation and Administrative infrastructure, allowing us to invest more in product licensing, acquisition and development activities. CDD: How can our readers find out more about your company? TA: For general information on TAGI Pharma and our product portfolio, visit our web site www.tagipharma.com, or call our customer support group at 855- 225-8244 or 815-624-7685. For questions related to establishing a business relation- ship with TAGI Pharma, call Kenny Harrington (Vice President of Sales & Marketing) at 815-624-8523 ext. 203. For more information, visit booth 4917, go online to www.tagipharma.com, call 855-225-8244 or email market- ing@tagipharma.com.